Ethics and Nanopharmacy: Value Sensitive Design of New Drugs

NanoEthics

Volumn 5, Issue 3, 2011, Pages 269-283

  Timmermans, Job ^a   Zhao, Yinghuan ^a,b   van den Hoven, Jeroen ^a  

^a DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Converging technologies; Ethical issue; ICT; Nanoinformatics; Nanopharmaceuticals; Personalized medicine; Social impact; Technological risk; Value sensitive design

Indexed keywords

EID: 84855360063     PISSN: 18714757     EISSN: 18714765     Source Type: Journal    
DOI: 10.1007/s11569-011-0135-x     Document Type: Article

References (62)

1. Action Grid (2010) The ACTION-Grid White Paper: Linking Biomedical Informatics, Grid Computing and Nanomedicine, http://www. action-grid. eu/documents/ACTION-Grid%20White%20Paper. pdf, retrieved 1-8-2011.
2. Allhoff F, Lin P, Moore M (2010) What is nanotechnology and why does it matter?: From science to ethics. Wiley-Blackwell, Oxford.
3. Allhoff F, Lin P (2006) What's so special about nanotechnology and nanoethics? Int J Appl Philos 20(2): 179-90.
4. Arnall AH (2003) Future technologies, today's choices: nanotechnology, artificial intelligence and robotics; a technical, political and institutional map of emerging technologies, Greenpeace Environmental Trust.
5. Bawa R, Johnson S (2009) Emerging Issues in Nanomedicine and Ethics. Nanotechnology & Society, p. 207-223, doi: 10. 1007/978-1-4020-6209-4_11.
6. Bawa R, Melethil S, Simmons WJ, Harris D (2008) Nanopharmaceuticals-patenting issues and FDA regulatory challenges. Am Bar Assoc SciTech Lawyer 5(2): 10-15.
7. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA (2008) Emerging nanopharmaceuticals. Nanomed Nanotech Biol Med 4(4): 273-282, Elsevier Inc. Retrieved from http://www. ncbi. nlm. nih. gov/pubmed/18640076.
8. Bennett-Woods D (2008) Nanotechnology: Ethics and society. CRC Press, Boca Raton.
9. Brownsword R (2009) Nanoethics: old wine, new bottles? J Consum Policy 32(4): 355-379, Springer Netherlands. Retrieved from http://www. springerlink. com/content/f020211848hrk548/?p=8ab7e3b0487c4949a3351d653023c58b& pi=0.
10. Califf RM (2004) Defining the balance of risk and benefit in the era of genomics and proteomics. Health Affairs 23(1): 77-87.
11. Casci T (2004) Doctor in a cell. Nat Rev Genet 5(6): 406. doi: 10. 1038/nrg1369.
12. Cummings ML (2006) Integrating ethics in design through the value-sensitive design approach. Sci Eng Ethics 12: 701-715. doi: 10. 1007/s11948-006-0065-0.
13. D'Silva J, van Calster G (2009) Taking temperature-A review of European Union regulation in nanomedicine. Eur J Health Law 16(3): 249-269.
14. Eaton MAW (2011) How do we develop nanopharmaceuticals under open innovation? Nanomed Nanotech Biol Med 7(4): 371-375.
15. Eaton M, Weltring KM (2010) The impact of the open innovation on (Nano-) Healthcare R& D in Europe. For: The European Technology Platform Nanomedicine (ETPN), www. etp-nanomedicine. eu, retrieved 20th August 2011.
16. Ebbesen M, Jensen TG (2006) Nanomedicine: techniques, potentials, and ethical implications. In: Journal of Biomedicine and Biotechnology. Volume 2006, Article ID51516, Pages 1-11.
17. European Commission (2008) Regulatory Aspects of Nanomaterials. COM (2008) 366, 17. 6. 2008.
18. Scientific committee on emerging and newly identified health risks (Scenihr) (2005). The appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious products of nanotechnologies. Available on line: http://nanobio-raise. org/group/editors/menus/main/activities/view. Retrieved: August 30, 2008.
19. European TechnologyPlatform on NanoMedicine (2005) Nanotechnology for Health: Vision paper and and Basis for a Strategic Research Agenda for NanoMedicine, ftp://ftp. cordis. europa. eu/pub/nanotechnology/docs/nanomedicine_visionpaper. pdf, retrieved 25th of August 2011.
20. Davis ME (2009) Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 61(13): 1189-1192, ISSN 0169-409X.
21. Friedman B (ed) (1997) Human values and the design of computer technology. Cambridge University Press and CSLI, Stanford University, New York.
22. Friedman B, Kahn PH (2000) New directions: A value-sensitive design approach to augmented reality. Proceedings of DARE 2000 on Designing augmented reality environments (pp. 163-164).
23. Friedman B, Kahn PH, Borning A (2002) Value sensitive design: Theory and methods. Engineering, 21(December), 1-8. Department of Computer Science, University of Washington.
24. Holm S (2006) Pharmacogenetics, race and global injustice. Dev World Bioethics 8(2): 82-88.
25. Gabellieri C, Frima H (2011) Nanomedicine in the European Commission policy for nanotechnology, Nanomedicine: Nanotechnology, Biology and Medicine, Available online 28 July 2011, ISSN 1549-9634, doi: 10. 1016/j. nano. 2011. 07. 003.
26. Graur F et al (2011) Ethical Issues in Nanomedicine, MEDITECH 2011. In Vlad S, Ciupa RV (eds), IFMBE Proceedings 36, pp. 9-12, 2011.
27. Grunwald A (2010) From speculative nanoethics to explorative philosophy of nanotechnology. NanoEthics 4: 91-101, Springer Netherlands. Retrieved from http://www. nanoarchive. org/9602/.
28. Guerra G (2008) European Regulatory Issues in Nanomedicine. NanoEthics 2(1): 87-97, Retrieved from http://www. springerlink. com/index/10. 1007/s11569-008-0031-1.
29. Heersmink R, van den Hoven J, van Eck NJ, van den Berg J (2011) Bibliometric mapping of computer and information ethics. Ethics Inform Technol 13(3): 241-249.
30. Helge K (2009) Emotional intelligence: The possibilities and pitfalls of affective computing software. In AALL Spectrum 14 (Dec. 2009). P 14-17.
31. Hongxuan Ren (2004) Attaching great importance to assessment for the safety for nanopharmaceuticals. Available online: http://www. gsstc. gov. cn/Plan/detail. php?dir=/&n_no=3561. Last available: July1, 2008.
32. Houdy P, Lahmani M, Marano F (Eds) (2011) Nanoethics and Nanotoxicology. Springer.
33. Koepsell D (2011) Innovation and nanotechnology: Converging technologies and the end of intellectual property. Bloomsbury Academic, London.
34. Lin P, Allhoff F (2008) Nanoscience and nanoethics: Defining the disciplines. In: Allhoff F, Lin P, Moor J, Weckert J (eds) Nanoethics: The social & ethical implications of nanotechnology. Wiley, Hoboken.
35. Maojo V, Martin-Sanchez F, Kulikowski C, Rodriguez-Paton A, Fritts M (2010) Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res 67(5): 481-489.
36. McGinn R (2010) Ethical responsibilities of nanotechnology researchers: a short guide. NanoEthics 4(1): 1-12.
37. Mehta MD (2004) The future of nanomedicine looks promising, but only if we learn from the past. In: Health Law Review, Vol. 13 Nbr. 1, December 2004.
38. Miller J (2003) Beyond biotechnology: FDA regulation on nanomedicine. Columbia Sci Technol Law Rev 2002-2003: 4.
39. Miller S, Selgelid M (2006) Ethical and philosophical consideration of the dual-use dilemma in the biological sciences. Centre for Applied Philosophy and Public Ethics (An Australian Research Council funded Special Research Centre), Australian National University and Charles Sturt University, Canberra.
40. Mills K, Fledderman C (2005) Getting the best from nanotechnology: approaching social and ethical implications openly and proactively. IEEE Technol Soc Mag 24(4): 18-26.
41. Mol A (2006) Proving or improving: on health care research as a form of self-reflection. Qualitative health research, 16.
42. Mol A (2008) The logic of care: Health and the problem of patient choice. Routledge, London.
43. Netzer C, Biller-Andorno N (2004) Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 18(4): 344-360.
44. Pison U, Welte T, Giersig M, Groneberg DA (2006) Nanomedicine for respiratory diseases. Springer, European Journal of Pharmacology.
45. Duquet D, Trottier E (2006) Ethics and nanotechnology: A basis for action. Commission de l'éthique de la science et de la technologie, Québec, Québec (Province).
46. Sheetz T, Vidal J, Pearson TD, Lozano K (2005) Nanotechnology: Awareness and societal concerns. Technology in Society 27(3): 329-345.
47. Sandberg A, Bostrom N (2006) Converging cognitive enhancements. Ann NY Acad Sci 1093: 201-227.
48. Spagnolo AG, Daloiso V (2009) Outlining ethical issues in nanotechnologies. Bioethics 23(7): 394-402. doi: 10. 1111/j. 1467-8519. 2007. 00623. x, September 2009. Available at SSRN: http://ssrn. com/abstract=1484038.
49. Sparrow R (2007) Revolutionary and familiar, inevitable and precarious: Rhetorical contradictions in enthusiasm for nanotechnology. NanoEthics 1(1).
50. Reynolds C, Picard R (2004) Affective sensors, privacy, and ethical contracts. In CHI '04 Extended Abstracts on Human Factors in Computing Systems (Vienna, Austria, April 24-29, 2004). CHI '04. ACM, New York, NY, 1103-1106.
51. Reynolds C, Picard RW (2005) Evaluation of affective computing systems from a dimensional metaethical position, 1st Augmented Cognition Conference, In conjunction with the 11th International Conference on Human-Computer Interaction, July 22-27, 2005, Las Vegas, NV.
52. Smart A, Martin P, Parker M (2004) Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 18(4): 322-342.
53. Swierstra T, Boenink M, Walhout B, van Est R (2009) Converging technologies, shifting boundaries. NanoEthics 3(3): 213-216, ISSN 1871-4757.
54. Timmermans J, Stahl BC, Ikonen V, Bozdag E (2010) The ethics of cloud computing: A conceptual review. Cloud Computing, HCI, & Design: Sustainability and Social Impacts, 2nd IEEE International Conference on Cloud Computing Technology and Science (CloudCom 2010), Indianapolis, USA.
55. van den Hoven MJ, Miller S, Pogge T (2012) The design turn in applied ethics. (Cambridge University Press) (Forthcoming).
56. van den Hoven MJ (2008) The tangled web of tiny things: privacy implications of nano-electronics. In: Allhoff F, Lin P (eds) Nanotechnology and society: current and emerging ethical issues. Springer, Heidelberg, pp 147-162.
57. van den Hoven MJ, Weckert J (2008) Information technology and moral philosophy. Cambridge University Press.
58. van de Poel IR (2008) How should we do nanoethics? A network approach for discerning ethical issues in nanotechnology. Nanoethics: Ethics for Technologies that Converge at the Nanoscale 2(1): 25-38.
59. Virdi J (2009) Bridging the knowledge gap: Examining potential limits in nanomedicine, Spontaneous Generations: A Journal for the History and Philosophy of Science; Vol 2, No 1: Frankenstein in Lilliput: Science at the Nanoscale.
60. Weber K (2006) The next step: privacy invasions by biometrics and ICT implants. Ubiquity 2006, November (Nov. 2006), 1-18.
61. Weckert J (2006) The control of scientific research: The case of nanotechnology. In: Tavani HT (ed) Ethics, computing, and genomics. Jones and Bartlett, Sudbury.
62. Weston AD, Hood L (2004) Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine introduction: paradigm changes in health care. J Proteome Res 3: 179-196.